Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

High Risk Anatomy Challenges ISCHEMIA Outcomes

According to this recent analysis published in JAHA, patients with stable Ischemic heart disease and high-risk anatomy benefit from revascularization at long term vs. the conservative treatment. 

Ischemia

This goes against the study presented by Reynolds H et al at AHA 2020. Dr. Reynold’s was a sub-study of the ISCHEMIA trial which had observed that even though anatomical complexity impacts prognosis, it cannot be modified by revascularization. 

The ISCHEMIA, published in NEJM, and all its sub studies, came to question everything we used to believe about chronic ischemic cardiomyopathy.  However, more and more studies shed light on the recommended strategies. 

9016 patients with stable ischemic heart disease and high-risk anatomy where included (3 vessels with >70% lesion, left main with >50% lesion or a combination of both).

The primary end point of all cause death or acute myocardial infarction was compared between patients receiving revascularization and those treated conservatively.


Read also: Diabetes and Peripheral Vascular Disease: Old Drugs, New Evidence.


5487 (61%) of patients received CABG (n=3312) or PCI (n=2175), whereas the remaining 3529 (39%) were managed conservatively.

Revascularization was associated with reduced MI rate and all cause rate. In addition, it was associated with longer life expectancy compared against the conservative treatment (p<0.001 for all points). 

Reduced events rate was similar between CABG (HR 0.64, CI 95% 0.59 to 0.70, p<0.001) and PCI (HR 0.61; CI 95% 0.57 to 0.66; p<0.001).

Conclusion

Revascularization in patient with stable ischemic heart disease and high-risk anatomy improves prognosis at long term compared against the conservative treatment. Coronary anatomy should be considered before recommending revascularization to treat these patients. 

JAHA-120-018104

Original Title: Long-Term Clinical Outcomes Following Revascularization in High-Risk Coronary Anatomy Patients With Stable Ischemic Heart Disease.

Reference: Kevin R. Bainey et al. J Am Heart Assoc. 2021;10:e018104.  DOI: 10.1161/JAHA.120.018104.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...